Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAD001 and Bevacizumab in Recurrent Ovarian Cancer
NCT01031381Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Sep 2010
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC), sponsored by University of Pittsburgh. Primary endpoint: Progression-free Survival at 6 months. Started Sep 2010; status: completed.
02
Drugs
everolimus
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT01031381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01031381.